

Press release

DEINOVE ANNOUNCES THE GREAT SUCCESS OF ITS SHARE CAPITAL INCREASE WITH SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS

- **Total demand of approximately €11.8 million, i.e. an oversubscription rate of 128% of the offer**
- **Full exercise of the extension clause bringing the issue size to €10.7 million**

Montpellier, 21 December 2015 – DEINOVE (Alternext Paris: ALDEI), a biotech company developing innovative processes for producing biofuels and bio-based chemicals from non-food biomass with its *Deinococcus* bacteria, announced today the great success of its capital increase with preferential subscription rights – launched on November 30, 2015 – oversubscribed by 128%.

Following the subscription period, which ended on December 14, 2015, the total demand amounted to approximately €11.8 million, for an initial amount of €9.3 million, i.e. a global subscription rate of 128%:

- 1,873,590 new shares were subscribed on an irreducible basis, representing approximately 90.9% of the new shares to be issued; and
- Reducible subscriptions amounted to 759,178 new shares and will, as a result, be satisfied only in part, i.e. for 497,046 new shares.

Consequently, the Company decided to fully exercise the extension clause of 15% of the size of the initial offer, raising the number of new shares to be issued from 2,061,423 to 2,370,636 shares. After the full exercise of the extension clause, the total gross proceeds of the transaction amounts to €10,667,862, issue premium included.

The Company's share capital, following the capital increase, will amount to €3,421,962.80, represented by 8,554,907 shares with a par value of €0.40 each.

The settlement and delivery as well as the admission to trading on the Alternext Paris market of the new shares are expected to take place on December 23, 2015. The new shares will carry full dividend rights and will be immediately fungible with existing shares of the Company and will be traded on the same trading line under the ISIN code FR0010879056.

The share capital increase with shareholders' preferential subscription rights was led by SwissLife Private Banking acting as Lead Manager and Bookrunner of the transaction. Brunswick Société d'Avocats was DEINOVE's counsel for the legal aspects of the operation.

"The unquestionable success of our share capital increase, in a complicated market environment, demonstrates our shareholders' confidence, both historic ones and newcomers. We would like to warmly thank all of them for their strong commitment", states Emmanuel Petiot, CEO of DEINOVE. "While the COP21 Conference concluded successfully with an historic agreement last week, these funds will be used to move toward the industrialization of our bioprocesses, and thus make us contribute to the transition toward an oil-free economy."

NOT TO BE PUBLISHED, TRANSMITTED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY,
IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA

About DEINOVE

DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the *Deinococci*. Taking advantage of the bacteria's unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro-factories" to produce high value-added products from non-food biomass. The Company's primary markets are 2nd-generation biofuels (DEINOL) and bio-based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally.

Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs almost 50 people in its offices and laboratories located in Montpellier, France.

More information at www.deinove.com

Contacts

DEINOVE

Emmanuel Petiot

CEO

Tel.: +33 (0)4 48 19 01 28

emmanuel.petiot@deinove.com

Coralie Martin

Communication, Marketing and IR Manager

Tel.: +33 (0)4 48 19 01 60

coralie.martin@deinove.com

ALIZE RP, Press Relations

Caroline Carmagnol / Wendy Rigal

Tel.: +33 (0)1 44 54 36 66

deinove@alizerp.com



Disclaimer

The offer was opened to the public in France.

The prospectus approved by the French Financial Markets Authority (the "AMF") on November 26, 2015 under number 15-607 includes DEINOVE's Document de Reference (the "Registration Document"), registered with the AMF on November 26, 2015 under number R.15-081, a securities note (the "Securities Note") and a summary of the prospectus (included in the securities note).

- **Availability of the reference document:** copies of the prospectus are available free of charge from DEINOVE, 1682, rue de la Valsière – Cap Sigma, ZAC Euromédecine II – 34790 Grabels – France (www.deinove.com) and from the AMF website (www.amf-france.org).
- **Risk factors:** DEINOVE wishes to draw the public's attention to chapter 4 (Risk factors) of the registration document filed with the AMF and to section 2 (Risk factors) of the Securities Note.

This press release and the prospectus registered with the French Financial Markets Authority (Autorité des marchés financiers) contain forward-looking statements. No guarantee is given as to these forecasts being achieved, which are subject to risks, including those described in the prospectus, and to the development of economic conditions, the financial markets and the markets in which DEINOVE operates.

NOT TO BE PUBLISHED, TRANSMITTED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY,
IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA

European Economic Area

The offer was opened to the public in France.

With respect to members of the European Economic Area other than France (the “Member States”) that have implemented the Prospectus Directive, no action has been undertaken or will be undertaken to make an offer to the public of securities requiring the publication of a prospectus in any Member State. Therefore, the Rights, the new shares and other securities mentioned in this press release may only be offered in Member States:

- to qualified investors as defined in the Prospectus Directive;
- to less than 100 or, if the Member State has transposed the relevant provision amending the Prospectus Directive, 150 natural or legal persons (other than qualified investors as defined in the Amending Prospectus Directive) per Member State; or
- in circumstances falling under the scope of Article 3 (2) of the Prospectus Directive.

For the purposes of this paragraph, (i) the expression “public offer of securities” in a given Member State means the communication to persons, in any form and by any means whatsoever, and containing sufficient information on the conditions of the offer and the securities to be offered to enable an investor to decide to purchase or subscribe said securities, as that definition has been, where appropriate, modified by the Member State in question, (ii) the expression “Prospectus Directive” means Directive 2003/71/EC of November 4, 2003, as transposed into the law of the Member State in question (as amended, including the Amending Prospective Directive when it has been transposed by each Member State), and (iii) the expression “Amending Prospectus Directive” means Directive 2010/73/EU of the European Parliament and of the Council of November 24, 2010. These sales restrictions relating to Member States apply in addition to any other restrictions applicable in Member States that have transposed the Prospectus Directive.

United Kingdom

This press release does not contain or constitute an invitation, inducement or solicitation to invest. This press release is intended solely for persons (i) who are not in the United Kingdom, (ii) who are investment professionals within the meaning of Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”), (iii) who are persons falling within the provisions of Article 49 (2) (a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, or (iv) who are persons to whom an invitation or inducement to engage in investment activity (within the meaning of the Financial Services and Markets Act 2000) may lawfully be made or caused to be made in the context of the issuance or sale of securities (all persons cited in (i), (ii), (iii) and (iv) together being designated as “Relevant Persons”).

This press release is aimed solely at Relevant Persons, and must not be used or relied upon by unauthorized persons. Any investment or investment activity in connection with this press release is reserved solely for Relevant Persons, and may only be made by Relevant Persons. This press release does not constitute an approval by the Financial Services Authority or any other regulatory authority in the United Kingdom within the meaning of Section 85 of the Financial Services and Markets Act 2000.

United States of America

This press release does not constitute an offer to sell securities or the solicitation of an offer to purchase securities in the United States of America. The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States in the absence of registration or an exemption from registration under the Securities Act. DEINOVE does not intend to register the offer in whole or in part in the United States of America, or to make a public offer in the United States of America.

NOT TO BE PUBLISHED, TRANSMITTED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY,
IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA